Does Salvage Transplant Show Benefit?
, 2025-05-07 12:47:00 TOPLINE: After a median follow-up of 99 months, salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) showed no survival benefit compared with continuous lenalidomide/dexamethasone in relapsed multiple myeloma. The absence of benefit was consistent across all subgroups, including patients with time to progression after frontline transplant beyond 48 months. METHODOLOGY: Researchers…